TY - JOUR
T1 - Cutaneous T-cell lymphoma
T2 - New immunomodulators
AU - Apisarnthanarax, Narin
AU - Duvic, Madeleine
N1 - Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2001
Y1 - 2001
N2 - During the most recent decades, much knowledge has been gained concerning the immunologic and pathologic mechanisms of CTCL. The development of immunomodulators aimed at correcting aberrations in immunology and cellular growth and differentiation reflects this increased understanding. This review of the currently available immune-response modifying drugs shows that recombinant forms of natural cytokines and retinoids can be developed with tolerable toxicity profiles and substantial efficacy. Although milestone drugs such as bexarotene have been approved by the FDA- for treatment of CTCL, other agents such as IL-12 may also have a place in treatment of the disease. Even though unapproved, IFN-alpha may be the most active single immunomodulating agent against CTCL. It seems that further delineation of CTCL cytokine profile changes and immunologic aberrations are key in developing effective immunomodulators that are able to reverse these alterations.
AB - During the most recent decades, much knowledge has been gained concerning the immunologic and pathologic mechanisms of CTCL. The development of immunomodulators aimed at correcting aberrations in immunology and cellular growth and differentiation reflects this increased understanding. This review of the currently available immune-response modifying drugs shows that recombinant forms of natural cytokines and retinoids can be developed with tolerable toxicity profiles and substantial efficacy. Although milestone drugs such as bexarotene have been approved by the FDA- for treatment of CTCL, other agents such as IL-12 may also have a place in treatment of the disease. Even though unapproved, IFN-alpha may be the most active single immunomodulating agent against CTCL. It seems that further delineation of CTCL cytokine profile changes and immunologic aberrations are key in developing effective immunomodulators that are able to reverse these alterations.
UR - http://www.scopus.com/inward/record.url?scp=0034754003&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034754003&partnerID=8YFLogxK
U2 - 10.1016/S0733-8635(05)70312-0
DO - 10.1016/S0733-8635(05)70312-0
M3 - Article
C2 - 11705358
AN - SCOPUS:0034754003
SN - 0733-8635
VL - 19
SP - 737
EP - 748
JO - Dermatologic Clinics
JF - Dermatologic Clinics
IS - 4
ER -